Billionaire venture capitalist Mark Cuban has not shied away from blasting President Donald Trump’s policy decisions, but he said Trump’s latest move just might work. The president announced on Tuesday plans to launch TrumpRx.gov, a federal-government-operated website to sell prescription drugs directly to consumers at discounted rates. Cuban founded Cost Plus Drugs, a similar direct-to-consumer (DTC) platform, in 2022 with the goal of disrupting the health care industry. The online marketplace sells hund ...

Core Insights - Stellar AfricaGold Inc. has reported significant assay results from its first drill hole at the Tichka Est Gold Project, indicating a promising gold system with confirmed mineralization at depth [1][10]. Drilling Results - The first drill hole TCK-001 intersected 13 meters of 6.12 g/t Au, including 2 meters of 22.28 g/t Au, and 16 meters of 1.98 g/t Au, including 1 meter of 11.55 g/t Au [3][4]. - A total of 492.8 meters of diamond core has been drilled across three holes in Zone B, with drilling progress averaging approximately 10.5 meters per day [3][11]. Geological Model - The mineralization is primarily hosted in sub-horizontal diorite sills, confirming the continuity of favorable lithology [3][9]. - Two well-defined mineralized zones were identified: Diorite 1 (16 m of 1.98 g/t Au) and Diorite 2 (13 m of 6.12 g/t Au) [9]. Operational Update - Drilling operations faced challenges such as fractured zones and weather-related impacts, but core recoveries exceeded 99% [12][16]. - The company plans to continue its 1,500-meter diamond drill program to test lateral continuity and down-dip extensions of the mineralized zones [17]. Future Plans - Management expressed confidence in the potential of the Tichka Est Gold Project and plans to expand the drilling program to explore additional targets [13]. - Surface reconnaissance exploration will continue across the 82 km² permit area, focusing on other areas of interest [13][14].

The company's accord with the president clears a cloud over the whole sector. ...

The company's accord with the president clears a cloud over the whole sector. ...

Core Insights - The article provides a market analysis of major pharmaceutical companies including Eli Lilly and Company, Merck & Company Inc, Biogen Inc, and Pfizer Inc, highlighting their performance and market trends [1] Company Summaries - **Eli Lilly and Company**: The company has shown significant growth in its revenue, driven by strong sales of its diabetes and cancer drugs. Recent product launches are expected to further enhance its market position [1] - **Merck & Company Inc**: Merck has reported a steady increase in its vaccine sales, particularly in the oncology segment. The company is focusing on expanding its pipeline with new drug candidates [1] - **Biogen Inc**: Biogen's performance has been impacted by competition in the Alzheimer's treatment market. The company is exploring strategic partnerships to bolster its research and development efforts [1] - **Pfizer Inc**: Pfizer continues to benefit from its COVID-19 vaccine sales, but faces challenges as demand stabilizes. The company is investing in new therapeutic areas to diversify its portfolio [1] Industry Trends - The pharmaceutical industry is experiencing a shift towards personalized medicine and biologics, with companies investing heavily in research and development to stay competitive [1] - Regulatory changes and pricing pressures are influencing market dynamics, prompting companies to adapt their strategies accordingly [1]

Core Viewpoint - Procter & Gamble Co is discontinuing its business operations in Pakistan as part of a global restructuring program, which includes winding down manufacturing and commercial activities in the region [1][2]. Group 1: Company Actions - P&G will cease operations in Pakistan, including its Gillette division, while continuing to serve consumers through other regional operations [1]. - The company announced plans to reduce its brand portfolio and cut up to 7,000 jobs globally over two years as part of its operational overhaul [2]. - A third-party distribution model will be adopted to serve consumers in Pakistan, with employees being considered for overseas placements or separation packages [6]. Group 2: Financial Performance - Gillette Pakistan's revenue nearly halved in the fiscal year ending June 2025, dropping from a record three billion rupees two years prior [3]. - The decision to exit follows a trend of multinational companies scaling back operations in Pakistan due to economic challenges, including profit-repatriation restrictions and weak demand [3][4]. Group 3: Industry Context - Other multinational companies, such as Shell, Pfizer, TotalEnergies, and Telenor, have also reduced their presence in Pakistan in recent years, highlighting broader economic difficulties despite the country's large population [4]. - The exit of P&G and other multinationals raises concerns about the business environment in Pakistan, with calls for improvements in infrastructure and regulatory conditions [7].

The maker of Tide detergent and other household items will wind down manufacturing and commercial activities of P&G Pakistan, as well as its razors division Gillette Pakistan Ltd., the Cincinnati-based company said in a statement. It will continue to serve consumers from other operations in the region, it said.P&G had in June announced it would pare its portfolio of brands and slash as many as 7,000 jobs over two years as part of an operations overhaul. The company also lowered its guidance to reflect the ...

Pfizer Inc. (NYSE:PFE) ranks among the top picks for a retirement portfolio. BMO Capital reaffirmed its Outperform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on September 23 in response to the company’s announcement of a new agreement in the obesity treatment market. Pixabay/Public Domain Following disappointments with its lotiglipron and danuglipron programs, the pharmaceutical giant has now made what BMO Capital refers to as a “thoughtful re-entry into the obesity metabolic space” with its ...

Ah, the stock market. That bastion of rational expectations, predictable trends, and calm, measured responses to geopolitical shifts. Or, if you’ve been paying attention to the past few years, a wild, unpredictable beast often dancing to the tune of a single, very loud, and frequently contradictory, trumpet. President Donald Trump, a man whose policy announcements often arrive via social media, has once again graced the financial world with a fresh batch of pronouncements, leading to the usual cocktail of r ...

HSBC sets a price target of $70 for Novo Nordisk (NYSE:NVO), indicating a potential 18.3% increase.The stock experienced a notable 6% increase following an agreement between Pfizer and the Trump administration, hinting at a positive outlook for pharmaceutical companies.President Trump's tariff threats could impact foreign pharmaceutical companies, but deals like Pfizer's offer a grace period, benefiting companies like Novo Nordisk.Novo Nordisk (NYSE:NVO) is a leading global healthcare company based in Denma ...